PPARγ Deacetylation Confers the Antiatherogenic Effect and Improves Endothelial Function in Diabetes Treatment
- 14 May 2020
- journal article
- research article
- Published by American Diabetes Association in Diabetes
- Vol. 69 (8), 1793-1803
- https://doi.org/10.2337/db20-0217
Abstract
Cardiovascular disease (CVD) is the leading cause of death in patients with diabetes, and tight glycemic control fails to reduce the risk of developing CVD. Thiazolidinediones (TZDs), a class of peroxisome proliferator–activated receptor γ (PPARγ) agonists, are potent insulin sensitizers with antiatherogenic properties, but their clinical use is limited by side effects. PPARγ deacetylation on two lysine residues (K268 and K293) induces brown remodeling of white adipose tissue and uncouples the adverse effects of TZDs from insulin sensitization. Here we show that PPARγ deacetylation confers antiatherogenic properties and retains the insulin-sensitizing effects of TZD while circumventing its detriments. We generated mice homozygous with mice with deacetylation-mimetic PPARγ mutations K268R/K293R (2KR) on an LDL-receptor knockout (Ldlr−/−) background. 2KR:Ldlr−/− mice showed smaller atherosclerotic lesion areas than Ldlr−/− mice, particularly in aortic arches. With rosiglitazone treatment, 2KR:Ldlr−/− mice demonstrated a residual antiatherogenic response and substantial protection against bone loss and fluid retention. The antiatherosclerotic effect of 2KR was attributed to the protection of endothelium, indicated by improved endothelium-dependent vasorelaxation and repressed expression of proatherogenic factors including inducible nitric oxide synthase, interleukin-6, and NADPH oxidase 2. Therefore, manipulating PPARγ acetylation is a promising therapeutic strategy to control risk of CVD in diabetes treatment.Keywords
Funding Information
- National Institutes of Health (R00DK97455, R01DK112943, P01HL087123)
This publication has 50 references indexed in Scilit:
- FGF21 and the Second Coming of PPARγCell, 2012
- Disruption of Endothelial Peroxisome Proliferator-Activated Receptor γ Accelerates Diet-Induced Atherogenesis in LDL Receptor-Null MiceArteriosclerosis, Thrombosis, and Vascular Biology, 2012
- Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylationNature, 2011
- Pioglitazone-Induced Reductions in Atherosclerosis Occur via Smooth Muscle Cell–Specific Interaction With PPARγCirculation Research, 2010
- Uncoupling of Acetylation from Phosphorylation Regulates FoxO1 Function Independent of Its Subcellular LocalizationOnline Journal of Public Health Informatics, 2010
- Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARγ by Cdk5Nature, 2010
- Fat and Beyond: The Diverse Biology of PPARγAnnual Review of Biochemistry, 2008
- Distinct profiles of endothelial gene expression in hyperpermeable regions of the porcine aortic arch and thoracic aortaAtherosclerosis, 2007
- SIRT1 controls endothelial angiogenic functions during vascular growthGenes & Development, 2007
- A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γNature, 2005